| A1A1 | A1A2 | A2A2 | A1A2 and A2A2 |
---|---|---|---|---|
Premenopausal | Â | Â | Â | Â |
   Controls, n (%) | 100 (43.5) | 99 (43.0) | 31 (13.5) | 130 (56.5) |
   Cases by stage |  |  |  |  |
Local, n (%) | 48 (43.6) | 50 (45.5) | 12 (10.9) | 62 (56.4) |
OR (95% CI)a | 1.0 | 1.02 (0.61–1.71) | 0.76 (0.35–1.66)b | 0.96 (0.58–1.56) |
Advanced, n (%) | 41 (53.2) | 30 (39.0) | 6 (7.8) | 36 (46.8) |
OR (95% CI)a | 1.0 | 0.63 (0.35–1.25) | 0.43 (0.16–1.16)c | 0.57 (0.32–1.01) |
Postmenopausal | Â | Â | Â | Â |
   Controls, n (%) | 127 (40.4) | 150 (47.8) | 37(11.8) | 187 (59.6) |
   Cases by stage |  |  |  |  |
Local, n (%) | 93 (40.8) | 105 (46.0) | 30 (13.2) | 135 (59.2) |
OR (95% CI)a | 1.0 | 1.01 (0.65–1.52) | 1.07 (0.57–2.16)d | 1.02 (0.68–1.53) |
Advanced, n (%) | 47 (35.6) | 73 (55.3) | 12 (9.1) | 85 (64.4) |
OR (95% CI)a | 1.0 | 0.98 (0.59–1.64) | 0.87 (0.37–2.05)e | 0.97 (0.62–1.53) |